Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Androgen receptor alterations in prostatic carcinoma

H Klocker1, Z Culig, A Hobisch

  • 1Department of Urology, University of Innsbruck, Austria.

The Prostate
|November 1, 1994
PubMed
Summary

Androgen receptor (AR) alterations in prostate cancer are linked to tumor progression. While AR expression levels don't predict treatment response, its heterogeneity and mutations may indicate therapy effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion].

Aktuelle Urologie·2009
Same author

The androgen receptor as mediator of gene expression and signal transduction pathways.

Trends in endocrinology and metabolism: TEM·2008
Same author

The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1.

Oncogene·2006
Same author

Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.

Endocrine-related cancer·2005
Same author

Antiandrogens in prostate cancer endocrine therapy.

Current cancer drug targets·2004
Same author

An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.

European journal of cancer (Oxford, England : 1990)·2004

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Androgen receptor (AR) mediates androgen action and is crucial for prostate cancer endocrine therapy.
  • Understanding AR expression and alterations is vital for managing prostate carcinoma progression and treatment outcomes.

Purpose of the Study:

  • To investigate the role of qualitative and quantitative alterations in AR expression in prostate cancer.
  • To explore the implications of AR expression and mutations on tumor progression and response to endocrine therapy.

Main Methods:

  • Analysis of AR expression in rat and human prostate tumor cell lines.
  • Immunohistochemical studies and binding assays on prostatic tumor specimens.
  • Detection of AR mutations in cell lines and primary tumor samples.

Related Experiment Videos

Main Results:

  • AR protein expression reduction was observed with increased tumor malignancy in cell lines.
  • ARs were present in all prostatic tumor types, irrespective of therapy response.
  • AR content did not correlate with endocrine therapy outcomes; heterogeneity of AR expression may predict responsiveness.
  • AR mutations, including point mutations and microsatellite alterations, were identified.

Conclusions:

  • AR structural alterations, rather than expression levels, may play a significant role in prostate cancer progression.
  • Heterogeneity in AR expression could serve as a biomarker for predicting therapy response in advanced prostate cancer.